Company CEO sells 120 shares in insider sale

In a recent transaction reported in an SEC filing, SAMUEL N HAZEN, the CEO of $HCA, divested 120 shares of the company on February 3, 2026, for a total amount of $59,661. This sale represented about 0.4% of their holdings in this particular class of stock, leaving them with a remaining ownership of 32,276 shares in $HCA.

Over the past half-year, $HCA insiders have actively engaged in trading the company’s stock. Among the insider transactions during this period, there were no purchases recorded but a total of 10 sales took place. The CEO, SAMUEL N HAZEN, executed seven of these sales, liquidating a substantial 42,877 shares for an estimated $21,483,274. Additionally, another key executive, MICHAEL S. CUFFE, the EVP and Chief Clinical Officer, completed two sales, disposing of 5,336 shares worth approximately $2,353,805, while MICHAEL R MCALEVEY, the EVP & Chief Legal & Admin Officer, sold 3,892 shares for an estimated sum of $1,843,990.

Moving beyond insider trades, data on hedge fund activities related to $HCA indicated diverse shifts in institutional investor positions. A total of 587 institutional investors augmented their stakes in $HCA, while 614 others reduced their holdings in the most recent quarter. Some significant movements observed within these institutional portfolios included UBS AM, which added 1,465,455 shares (+74.5%) totaling an estimated $624,576,921 in Q3 2025. In contrast, LONGVIEW PARTNERS (GUERNSEY) LTD decreased their holding by 1,287,869 shares (-82.4%) amounting to approximately $548,889,767 in the same quarter. It is essential for investors to monitor such activities to stay informed about prevailing market trends.

In terms of revenues, $HCA reported total revenues of $19.5B in Q4 2025, reflecting a notable increment of 6.72% compared to the corresponding period the previous year. Such financial indicators are crucial for investors and analysts to assess the performance and trajectory of a company over time.

Moreover, congressional members were also engaged in stock trading related to $HCA, with two transactions occurring in the past half-year. Among these trades, one was a purchase, and the other was a sale, underscoring the diverse activities surrounding $HCA stock within various investor groups. Detailed tracking of these trades provides valuable insights for market participants to make informed decisions.

Analyst reports on $HCA have been largely favorable, with 13 buy ratings and 1 sell rating issued by Wall Street analysts. Recent ratings from several firms, including Barclays, Jefferies, Deutsche Bank, Truist Securities, and Oppenheimer, among others, have reiterated positive outlooks on the stock. Analyst forecasts and price targets contribute valuable information for investors seeking to gauge market sentiment and future performance expectations.

In summation, monitoring insider trades, hedge fund activities, revenue reports, congressional stock trading, analyst ratings, and price targets for $HCA can equip investors with critical data to navigate the dynamic landscape of financial markets effectively. It is imperative for investors to remain vigilant and informed to make strategic investment decisions aligned with their financial goals and risk tolerance levels.